文献速递肝病

超重年数、多基因风险与非酒精性脂肪性肝病、显著纤维化及肝硬化的纵向关联

Longitudinal association between overweight years, polygenic risk and NAFLD, significant fibrosis and cirrhosis.
PubMed 文献 · Aliment Pharmacol Ther · 2023-03-16

基于Framingham心脏研究前瞻性队列的纵向分析纳入2478名成人,评估超重年数(BMI≥25 kg/m2的持续时间与严重程度乘积)与遗传风险对肝脂肪和纤维化的关联。结果显示超重年数每增加1个标准差与非酒精性脂肪性肝病(aOR 3.53)、临床显著纤维化(aOR 1.60)和肝硬化(aOR 1.81)均强相关,高多基因风险与肝脂肪及临床显著纤维化显著相关。

要点

  • 超重年数每增加1个标准差,非酒精性脂肪性肝病风险aOR 3.53(95%CI 3.10-4.02)。
  • 超重年数每增加1个标准差,临床显著纤维化aOR 1.60(95%CI 1.40-1.84)。
  • 超重年数每增加1个标准差,肝硬化aOR 1.81(95%CI 1.38-2.37)。

核心结论

  • 超重年数与非酒精性脂肪性肝病、临床显著纤维化及肝硬化强相关,结合多基因风险可能有助于界定非酒精性脂肪性肝病的轨迹。

研究设计与样本

  • 基于Framingham心脏研究前瞻性成人队列的纵向分析,纳入接受基因分型和振动控制瞬时弹性成像联合受控衰减参数检查者。

主要发现

  • 样本2478人(54%女性),平均年龄40(±8.5)岁,平均BMI 26.5(±5.1)kg/m2,平均随访14(±0.9)年,每人接受三次研究访视。
  • 非酒精性脂肪性肝病患病率28.3%(n=700),207人(8.4%)有临床显著纤维化。
  • 年龄、性别和糖尿病调整的多变量分析中,超重年数(每标准差)与非酒精性脂肪性肝病(aOR 3.53 [95%CI: 3.10-4.02],p<0.001)、临床显著纤维化(aOR 1.60 [95%CI: 1.40-1.84],p<0.001)和肝硬化(aOR 1.81 [95%CI: 1.38-2.37],p<0.001)强相关。
  • 高多基因风险与肝脂肪和临床显著纤维化显著相关(p<0.05)。

关键数值与推荐

  • 超重年数定义为BMI≥25 kg/m2的持续时间与严重程度的乘积。
  • 肝脂肪遗传变异评估PNPLA3、TM6SF2、GCKR;纤维化遗传变异评估PNPLA3、TM6SF2、HSD17B13,并计算多基因风险评分。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adiposity amplifies the genetic risk of non-alcoholic fatty liver disease (NAFLD). AIM: We evaluated the association between overweight-years, a cumulative exposure based on the product of the duration and severity of excess body weight (body mass index (BMI) ≥ 25 kg/m2 ), and genetic risk on liver fat and fibrosis. METHODS: This is a longitudinal analysis derived from a prospective cohort of adults in the Framingham Heart Study who underwent genotyping and vibration-controlled-transient-elastography with controlled attenuation parameter. Univariable and multivariable linear and logistic regression analyses were used to assess the association between overweight-years and liver fat and fibrosis. The association between genetic variants of liver fat (PNPLA3, TM6SF2, GCKR) and fibrosis (PNPLA3, TM6SF2, HSD17B13) was also assessed using a polygenic risk score. RESULTS: Our sample included 2478 participants (54% women) with mean age and BMI of 40 (±8.5) years and 26.5(±5.1) kg/m2 , respectively. The mean follow-up was 14(±0.9) years, and each participant underwent three study visits. The prevalence of NAFLD was 28.3% (n = 700), and 207 (8.4%) had clinically significant fibrosis. In age-, sex- and diabetes-adjusted multivariable analyses, overweight-years (per SD) had a strong association with NAFLD (aOR 3.53 [95% CI: 3.10-4.02], p < 0.001), clinically significant fibrosis (aOR 1.60 [95% CI: 1.40-1.84], p < 0.001) and cirrhosis (aOR 1.81 [95% CI: 1.38-2.37], p < 0.001). High-polygenic risk was significantly associated with liver fat and clinically significant fibrosis (p < 0.05). CONCLUSION: Overweight-years is strongly associated with NAFLD and clinically significant fibrosis and combined with polygenic risk may assist in defining the trajectory of NAFLD.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Ajmera V, Wang N, Xu H, et al. Longitudinal association between overweight years, polygenic risk and NAFLD, significant fibrosis and cirrhosis. Aliment Pharmacol Ther. 2023. PMID: 36924053. doi:10.1111/apt.17452

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。